Mizuho Cuts Cooper Companies (NASDAQ:COO) Price Target to $90.00

Cooper Companies (NASDAQ:COO) had its price target decreased by Mizuho from $105.00 to $90.00 in a research report released on Wednesday,Benzinga reports. Mizuho currently has an outperform rating on the medical device company’s stock.

COO has been the topic of several other research reports. Wall Street Zen cut shares of Cooper Companies from a “buy” rating to a “hold” rating in a research report on Saturday, July 12th. Robert W. Baird reduced their price target on shares of Cooper Companies from $107.00 to $97.00 and set an “outperform” rating on the stock in a research report on Friday, May 30th. Wells Fargo & Company reduced their price target on shares of Cooper Companies from $118.00 to $93.00 and set an “overweight” rating on the stock in a research report on Friday, May 30th. Needham & Company LLC upgraded shares of Cooper Companies from a “hold” rating to a “buy” rating and set a $94.00 price target on the stock in a research report on Tuesday, June 17th. Finally, UBS Group upgraded shares of Cooper Companies to a “buy” rating in a research report on Tuesday, June 17th. Four equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $97.20.

Cooper Companies Stock Performance

COO opened at $72.63 on Wednesday. The company has a current ratio of 2.10, a quick ratio of 1.23 and a debt-to-equity ratio of 0.30. Cooper Companies has a 12-month low of $65.00 and a 12-month high of $112.38. The company has a market cap of $14.52 billion, a price-to-earnings ratio of 35.26, a PEG ratio of 1.79 and a beta of 0.99. The company’s 50 day moving average is $74.03 and its 200 day moving average is $82.05.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings results on Thursday, May 29th. The medical device company reported $0.96 earnings per share for the quarter, beating the consensus estimate of $0.93 by $0.03. Cooper Companies had a net margin of 10.39% and a return on equity of 9.60%. The business had revenue of $1 billion for the quarter, compared to the consensus estimate of $995.12 million. During the same quarter in the previous year, the firm earned $0.85 earnings per share. The company’s revenue for the quarter was up 6.3% on a year-over-year basis. On average, equities research analysts predict that Cooper Companies will post 3.98 EPS for the current year.

Institutional Trading of Cooper Companies

A number of hedge funds have recently added to or reduced their stakes in COO. T. Rowe Price Investment Management Inc. lifted its position in shares of Cooper Companies by 2.1% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 7,678,965 shares of the medical device company’s stock valued at $705,928,000 after buying an additional 155,233 shares during the last quarter. JPMorgan Chase & Co. lifted its position in shares of Cooper Companies by 3.4% during the first quarter. JPMorgan Chase & Co. now owns 5,177,008 shares of the medical device company’s stock valued at $436,681,000 after buying an additional 172,485 shares during the last quarter. Geode Capital Management LLC lifted its position in shares of Cooper Companies by 2.3% during the fourth quarter. Geode Capital Management LLC now owns 4,906,463 shares of the medical device company’s stock valued at $449,907,000 after buying an additional 109,907 shares during the last quarter. Goldman Sachs Group Inc. lifted its position in shares of Cooper Companies by 17.0% during the first quarter. Goldman Sachs Group Inc. now owns 4,734,327 shares of the medical device company’s stock valued at $399,340,000 after buying an additional 686,751 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD lifted its position in shares of Cooper Companies by 12.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,954,877 shares of the medical device company’s stock valued at $333,595,000 after buying an additional 425,400 shares during the last quarter. 24.39% of the stock is owned by hedge funds and other institutional investors.

About Cooper Companies

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.